Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-β (Aβ) and the formation of neurofibrillary tangles. Although the amyloid cascade hypothesis underscores the centrality of Aβ accumulation, the precise initiators of this process remain unknown.
Objective
In this study, we investigate the potential role of Esophageal Cancer-Related Gene 4 (ECRG4) in AD. We hypothesized that ECRG4, which is associated with cognitive impairment and upregulated in AD, directly contributes to amyloid pathology.
Methods
We performed cell-based assays, co-immunoprecipitation, in vivo experiments using APPNL-G-F/NL-G-F knock-in mouse, and immunohistochemistry of human hippocampal sections.
Results
ECRG4(133–148) associated with the amyloid precursor protein (APP) intracellular domain (AICD), leading to increased APP/Aβ accumulation. Furthermore, intracerebral injection of synthetic ECRG4(133–148) into AD model mice significantly augmented APP/Aβ deposition. Notably, the co-localization of ECRG4(133–148)-containing peptides with AICD-containing peptides increased with AD severity in human hippocampal tissue.
Conclusions
Our findings establish that the carboxy-terminal fragment of ECRG4 acts as a potential initiator of amyloid pathology in AD through its interaction with AICD.
BertramLLillCMTanziRE. The genetics of Alzheimer disease: back to the future. Neuron2010; 68: 270–281.
2.
ZlokovicBV. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci2011; 12: 723–738.
3.
QuerfurthHWLaFerlaFM. Alzheimer’s disease. N Engl J Med2010; 362: 329–344.
4.
JackCRJr.HoltzmanDM. Biomarker modeling of Alzheimer’s disease. Neuron2013; 80: 1347–1358.
5.
YueCMDengDJBiMX, et al.Expression of ECRG4, a novel esophageal cancer-related gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma. World J Gastroenterol2003; 9: 1174–1178.
6.
GotzeSFeldhausVTraskaT, et al.ECRG4 Is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma. BMC Cancer2009; 9: 447.
7.
LiLWYuXYYangY, et al.Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo. Int J Cancer2009; 125: 1505–1513.
8.
KujuroYSuzukiNKondoT. Esophageal cancer-related gene 4 is a secreted inducer of cell senescence expressed by aged CNS precursor cells. Proc Natl Acad Sci U S A2010; 107: 8259–8264.
9.
XuPTLiYJQinXJ, et al.Differences in apolipoprotein E3/3 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease. Neurobiol Dis2006; 21: 256–275.
10.
PodvinSGonzalezAMMillerMC, et al.Esophageal cancer related gene-4 is a choroid plexus-derived injury response gene: evidence for a biphasic response in early and late brain injury. PLoS One2011; 6: e24609.
11.
NakataniYKiyonariHKondoT. Ecrg4 deficiency extends the replicative capacity of neural stem cells in a Foxg1-dependent manner. Development2019; 146: dev168120.
12.
GonzalezAMPodvinSLinSY, et al.Ecrg4 expression and its product augurin in the choroid plexus: impact on fetal brain development, cerebrospinal fluid homeostasis and neuroprogenitor cell response to CNS injury. Fluids Barriers CNS2011; 8: 6.
13.
DangXCoimbraRMaoL, et al.Open reading frame mining identifies a TLR4 binding domain in the primary sequence of ECRG4. Cell Mol Life Sci2019; 76: 5027–5039.
14.
BairdACoimbraRDangX, et al.Cell surface localization and release of the candidate tumor suppressor Ecrg4 from polymorphonuclear cells and monocytes activate macrophages. J Leukoc Biol2012; 91: 773–781.
15.
LeeJDangXBorboaA, et al.Thrombin-processed Ecrg4 recruits myeloid cells and induces antitumorigenic inflammation. Neuro Oncol2015; 17: 685–696.
16.
MoriguchiTKaneumiSTakedaS, et al.Ecrg4 contributes to the anti-glioma immunosurveillance through type-I interferon signaling. Oncoimmunology2016; 5: e1242547.
17.
GoldGBourasCKovariE, et al.Clinical validity of Braak neuropathological staging in the oldest-old. Acta Neuropathol2000; 99: 579–582.
18.
SelfWKHoltzmanDM. Emerging diagnostics and therapeutics for Alzheimer disease. Nat Med2023; 29: 2187–2199.
19.
SaitoTMatsubaYMihiraN, et al.Single App knock-in mouse models of Alzheimer’s disease. Nat Neurosci2014; 17: 661–663.
20.
ChaoCCKanDLoTH, et al.Induction of neural differentiation in rat C6 glioma cells with taxol. Brain Behav2015; 5: e00414.
21.
KondoTRaffM. The Id4 HLH protein and the timing of oligodendrocyte differentiation. EMBO J2000; 19: 1998–2007.
22.
TakanagaHTsuchida-StraetenNNishideK, et al.Gli2 is a novel regulator of sox2 expression in telencephalic neuroepithelial cells. Stem Cells2009; 27: 165–174.
23.
KondoT. Selective eradication of pluripotent stem cells by inhibiting DHODH activity. Stem Cells2021; 39: 33–42.
24.
HouJUejimaTTanakaM, et al.EVA1-antibody Drug conjugate is a new therapeutic strategy for eliminating glioblastoma-initiating cells. Neuro Oncol2025; 27: 682–694.
25.
DeMonteLPorcelliniSTafiE, et al.EVA Regulates thymic stromal organisation and early thymocyte development. Biochem Biophys Res Commun2007; 356: 334–340.
26.
NishideKNakataniYKiyonariH, et al.Glioblastoma formation from cell population depleted of Prominin1-expressing cells. PLoS One2009; 4: e6869.
27.
HideTTakezakiTNakataniY, et al.Combination of a ptgs2 inhibitor and an epidermal growth factor receptor-signaling inhibitor prevents tumorigenesis of oligodendrocyte lineage-derived glioma-initiating cells. Stem Cells2011; 29: 590–599.
28.
ZhangLIkedaNTakedaS, et al.Plasma ECRG4 as a novel diagnostic marker for Alzheimer’s disease associated with oligodendrocyte dysfunction. Am J Transl Res2026; 18: 3765–3782.
29.
LauritzenIPardossi-PiquardRBourgeoisA, et al.Does intraneuronal accumulation of carboxyl-terminal fragments of the amyloid precursor protein trigger early neurotoxicity in Alzheimer’s disease?Curr Alzheimer Res2019; 16: 453–457.
30.
TakasugiNKomaiMKaneshiroN, et al.The pursuit of the “inside” of the amyloid hypothesis-is C99 a promising therapeutic target for Alzheimer’s disease?Cells2023; 12: 454.
31.
LaiAGibsonAHopkinsCR, et al.Signal-dependent trafficking of beta-amyloid precursor protein-transferrin receptor chimeras in Madin-Darby canine kidney cells. J Biol Chem1998; 273: 3732–3739.
32.
UhlikMTTempleBBencharitS, et al.Structural and evolutionary division of phosphotyrosine binding (PTB) domains. J Mol Biol2005; 345: 1–20.
33.
GrimmMOMettJStahlmannCP, et al.Neprilysin and Abeta clearance: impact of the APP intracellular domain in NEP regulation and implications in Alzheimer’s disease. Front Aging Neurosci2013; 5: 98.
34.
SaricTGraefCIGoldbergAL. Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. J Biol Chem2004; 279: 46723–46732.
35.
AbramsonJAdlerJDungerJ, et al.Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature2024; 630: 493–500.
36.
LiCDJunaidMChenH, et al.Helix-switch enables C99 dimer transition between the multiple conformations. J Chem Inf Model2019; 59: 339–350.
37.
PerrinFPapadopoulosNSuelvesN, et al.Dimeric transmembrane orientations of APP/C99 regulate gamma-secretase processing line impacting signaling and oligomerization. iScience2020; 23: 101887.
38.
MullerTSchrotterALoosseC, et al.A ternary complex consisting of AICD, FE65, and TIP60 down-regulates Stathmin1. Biochim Biophys Acta2013; 1834: 387–394.
39.
LeCherJCNowakSJMcMurryJL. Breaking in and busting out: cell-penetrating peptides and the endosomal escape problem. Biomol Concepts2017; 8: 131–141.
40.
GrasselliCFerrariDZalfaC, et al.Toll-like receptor 4 modulation influences human neural stem cell proliferation and differentiation. Cell Death Dis2018; 9: 280.
41.
Calvo-RodriguezMde la FuenteCGarcia-DurilloM, et al.Aging and amyloid beta oligomers enhance TLR4 expression, LPS-induced Ca(2+) responses, and neuron cell death in cultured rat hippocampal neurons. J Neuroinflammation2017; 14: 24.
42.
PodvinSMillerMCRossiR, et al.The orphan C2orf40 gene is a neuroimmune factor in Alzheimer’s disease. JSM Alzheimers Dis Relat Dement2016; 3: 1020.
43.
SykováENicholsonC. Diffusion in brain extracellular space. Physiol Rev2008; 88: 1277–1340.
44.
WatersJ. The concentration of soluble extracellular amyloid-beta protein in acute brain slices from CRND8 mice. PLoS One2010; 5: e15709.
45.
YamadaMChibaTSasabeJ, et al.Implanted cannula-mediated repetitive administration of Abeta25-35 into the mouse cerebral ventricle effectively impairs spatial working memory. Behav Brain Res2005; 164: 139–146.
46.
LeeDSChoiJKimSH, et al.Ameliorating effects of HX106N, a water-soluble botanical formulation, on Abeta25-35-induced memory impairment and oxidative stress in mice. Biol Pharm Bull2014; 37: 954–960.
47.
KimHYLeeDKChungBR, et al.Intracerebroventricular injection of amyloid-beta peptides in normal mice to acutely induce Alzheimer-like cognitive deficits. J Vis Exp2016; 109: 53308.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
